HEALTH IN CODE

What HEALTH IN CODE does

Health in Code is a Spain-headquartered clinical genomics company that provides genetic diagnostic services, proprietary analysis kits, and bioinformatics software to healthcare professionals across more than 30 countries. Founded in 2006 and reconstituted through a 2020 combination of four entities, the company has evolved from a niche inherited cardiovascular disease laboratory into a multi-specialty clinical genomics provider spanning 16 clinical areas, including cardiology, oncology, neurology, pharmacogenetics, immunology, nephrology, prenatal genetics, and rare-disease diagnostics.

The company operates an integrated NGS-based technology stack anchored in Whole Genome Sequencing, trio whole-exome analysis, PacBio Revio long-read HiFi sequencing, and Olink Explore high-throughput proteomics. Spain's first NovaSeq X Plus installation is in operation. Internally developed software includes the AEMPS-licensed Datagenomics client portal and HiC Mutaciones variant interpretation platform, complemented by the CE-IVD-marked Action PharmaKitDx panel covering 335 pharmacogenes. The company runs authorized laboratories in A Coruña, Valencia, and Málaga, with additional offices in Madrid, Granada, and Lisbon, and maintains channel partner laboratories in Germany and Portugal.

The company pursues a B2B go-to-market targeting cardiologists, neurologists, oncologists, hospital laboratories, and research institutions. Revenue is generated through six streams: in-house laboratory diagnostic services, CE-IVD kit and equipment sales to partner laboratories, expert variant interpretation, clinical-genetic reporting, recurring access to proprietary bioinformatics software under AEMPS healthcare license 8581-PS, and proteomics services. Pricing is quote-based and not publicly disclosed. Health in Code is privately held by private equity sponsors — Alantra Private Equity leads ownership after closing a €155 million healthcare continuation fund in February 2026 anchored by Hayfin Capital Management, with Mérieux Equity Partners acquiring a 20% minority stake through its MP4 buyout fund in the same transaction. Revenue has grown from €24 million to over €50 million, with management and investor partners targeting €100 million within five years.

Name

HEALTH IN CODE

Legal name

HEALTH IN CODE, S.L.

Website

http://www.healthincode.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Short description

Health in Code is a Spain-based clinical genomics company providing NGS-based diagnostic services, CE-IVD analysis kits, and proprietary bioinformatics software to healthcare professionals across 16 medical specialties in more than 30 countries.

Ownership category

akta.pro rank

Product category

Clinical Genetic Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Clinical genomics
• Genetic diagnostic services
• NGS laboratory services
• Pharmacogenetic testing
• Bioinformatics software

Headquarters

HQ city

A Coruña

HQ country

Spain

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Genetic Diagnostic Laboratory Services: Complete genetic studies performed entirely in company laboratories, from sample receipt to specialized clinical report generation. Services include comprehensive genetic testing across 16 clinical areas including cardiology, oncology, neurology, and rare diseases.
2. Genetic Analysis Kits: Development and manufacturing of diagnostic disease kits for use in specialized laboratories. Kits include sequencing reagents, bioinformatics software access, database access, and equipment leasing with full process support and guidance.
3. Variant Interpretation Services: Clinical and molecular interpretation of genetic studies performed by partner centers, determining pathogenicity of each variant according to the latest international guidelines.
4. Clinical Genetic Reports: Clinical-genetic reports of sequencing results from partner center laboratories, prepared by expert teams of medical specialists and biologists specialized in genetic diagnosis of hereditary diseases.
5. Bioinformatics Software Platforms: Access to proprietary software platforms (Datagenomics and HiC Mutaciones) for variant filtering, analysis, and interpretation. Licensed under AEMPS healthcare license.
6. Proteomics Services: Olink Explore proteomics services for biomarker discovery and analysis in drug development, clinical research, and basic biological science studies.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Health in Code provides comprehensive genetic diagnostic services using Next-Generation Sequencing (NGS) and complementary technologies across 16 clinical areas including cardiology, oncology, neurology, and pharmacogenetics. The company combines in-house clinical laboratory testing (Whole Genome Sequencing, Trio Exome, NIPT) with proprietary CE-IVD genetic analysis kits and AEMPS-licensed bioinformatics platforms (Datagenomics, HiC Mutaciones) sold to specialist partner laboratories. Its portfolio also includes Olink Explore proteomics services and PacBio Revio long-read sequencing for research and clinical applications.

Product overview

Health in Code is a clinical genomics company offering an integrated model combining NGS-based diagnostic services, genetic analysis kits, and proprietary bioinformatics tools. The portfolio includes Whole Genome Sequencing (WGS) and Trio Exome services for comprehensive genetic diagnosis, the Genatal non-invasive prenatal test, and Olink Explore proteomics platform for protein biomarker analysis. PacBio Revio long-read sequencing provides third-generation sequencing capabilities. The company operates proprietary software platforms including Datagenomics client portal and HiC Mutaciones bioinformatics software (AEMPS licensed). Analysis kits are available across 16 clinical specialty areas. The company holds subsidiaries Genycell Biotech, Genologica, and Imegen Agro, with international operations spanning 30+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• Genycell Biotech: Biotechnology brand under Health in Code umbrella
• Genologica
• Imegen Agro
• Genatal
• Plushic
• Datagenomics
• HiC Mutations

Products and services

• Whole Genome Sequencing (WGS) Complete genome sequencing service providing comprehensive genetic information for diagnosis of complex genetic diseases, using efficient and accessible methodology. Aimed at healthcare professionals requiring whole-genome-level analysis.
• Trio Exome (Exoma completo en trío) Family trio whole exome sequencing providing the highest diagnostic yield for complex genetic diseases, delivering faster results and more informed clinical decisions for pediatric and complex cases.
• Genatal Non-invasive prenatal test (NIPT) for prenatal genetic screening, offered under the Genatal brand for obstetricians and clinical specialists.
• Olink Explore Proteomics High-throughput proteomics platform using Proximity Extension Assay (PEA) technology combined with NGS for simultaneous quantification of hundreds to thousands of protein biomarkers in body fluids, available as a certified Olink Explore service offering.
• PacBio Revio Long-Read Sequencing Third-generation HiFi long-read sequencing service from PacBio Revio providing precision, scalability and simplicity for comprehensive genomic analysis offered by Health in Code as a certified service provider.
• Datagenomics Proprietary client portal platform for genetic study requests, variant filtering, and results report download, including bioinformatics analysis capabilities. Licensed by AEMPS under license number 8581-PS.
• HiC Mutaciones Proprietary in-house bioinformatics analysis software for genetic variant filtering and interpretation, licensed by AEMPS under license number 8581-PS.
• Analysis Kits Genetic diagnostic test kits for specialized laboratory use across cardiology, oncology, neurology, pharmacogenetics, and other clinical specialties; sold to partner laboratories with bioinformatics software, database access, and equipment support.
• Action PharmaKitDx CE-marked targeted NGS panel covering 335 pharmacogenes for pharmacogenetic testing, delivering >99.3% accuracy, sensitivity, specificity, and positive predictive value with 98% concordance against GeT-RM reference materials across multiple Illumina platforms.

Quantifiable outcome

• Revenue growth from €24M to over €50M, more than doubling under Alantra's investment
• +4 more outcomes

Named customers5 records

Segments17 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered minor, core and secondary.

• DLA PiperminorImplementation/ SI/ Consulting Partner · 24 February 2026DLA Piper served as legal advisor to Mérieux Equity Partners on the acquisition of a significant minority stake in Health in Code. This was a transactional legal advisory role.
• Genologica MédicacoreStrategic or Co-development Partner · 31 July 2023Health in Code acquired Genologica Médica, a Málaga-based genetic diagnostics company specializing in disease prevention, diagnosis, prognosis, and treatment of hereditary or genetic diseases. Both companies operate independently in sales and operations but collaborate in research and development to enhance personalized medicine offerings. Genologica is now one of Health in Code's brands alongside Genycell Biotech and Imegen Agro.
• PacBiocoreTechnology or IntegrationTechnology partnership for long-read sequencing using PacBio's Revio platform. Health in Code offers Long-Read Sequencing services leveraging PacBio HiFi technology for precise, scalable, and simple genomic analysis. The company is a certified PacBio service provider.
• OlinkcoreTechnology or IntegrationHealth in Code is the first certified Olink Explore Service Provider in Spain, offering proteomics services using Olink's PEA technology combined with NGS for scalable biomarker analysis. Provides access to Olink Explore 3072 and Olink Reveal platforms for drug development, clinical research, and biomarker discovery.
• IlluminacoreTechnology or IntegrationTechnology partnership for NGS platforms. Health in Code installed Spain's first NovaSeq X Plus, reaffirming leadership in genomic sequencing capacity and commitment to whole genome studies. Validated pharmacogenetic panel on multiple Illumina platforms.
• German Partner LaboratoriessecondaryChannel Partner/ Reseller/ DistributorStrategic agreements with laboratories in Germany for distribution of Health in Code products and services. Part of the company's international expansion strategy.
• Portuguese Partner LaboratoriessecondaryChannel Partner/ Reseller/ DistributorStrategic agreements with laboratories in Portugal for distribution of Health in Code products and services. The company has a Lisbon office to support these partnerships.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Invitae: US-based clinical genetic testing company (now operating under Labcorp) offering NGS-based hereditary disease panels across cardiology, oncology, neurology, and rare diseases. Closely aligned with HIC's specialty medical genetics testing portfolio and integrated kit/software/services model.
• GeneDx: US clinical genomics company (owned by Sema4/Moonlake; went public via SPAC) specializing in rare disease exome and genome sequencing with proprietary interpretation platform. Directly comparable to HIC's trio exome, whole genome sequencing, and clinical variant interpretation services.
• PreventionGenetics: US clinical DNA testing laboratory (acquired by Exact Sciences) offering whole genome sequencing, exome sequencing, and multi-specialty hereditary disease panels. Closely comparable to HIC's WGS/trio exome services and multi-area clinical genetic testing.
• Ambry Genetics: US-based clinical genetic testing laboratory (acquired by Konica Minolta) offering hereditary cancer, cardiology, and rare disease NGS panels. Direct functional peer to HIC's multi-specialty clinical genetic testing services and CE-IVD-grade diagnostic offerings.
• Fulgent Genetics: US-based clinical NGS laboratory offering hereditary cancer, cardiovascular, neurological, and reproductive genetic testing through proprietary bioinformatics platform. Direct peer in the clinical genomics services model with comparable test menu breadth and technology partnerships.
• Eurofins Genomics: European division of Eurofins Scientific offering genomic services including NGS, Sanger sequencing, and bioinformatics to pharma, academic, and clinical customers. A pan-European peer whose footprint overlaps with HIC's 30+ country laboratory services in Europe.
• Centogene: Germany-based clinical genomics company focused on rare disease and hereditary diagnostics with multi-omic analysis (genomics, proteomics, metabolomics). Direct comparator to HIC's specialty diagnostic lab model, CE-IVD products, and rare-disease clinical reporting across European markets.

Broad incumbents

• Synlab: Europe's largest medical diagnostics services provider offering clinical lab testing across geographies and specialties. A broader incumbent whose medical laboratory operations overlap HIC's clinical lab segment though it is not specialized in hereditary genomics.
• Cerba Healthcare: European clinical reference laboratory offering specialty testing in genetics, infectious disease, and clinical pathology across multiple European and African markets. Comparable broad European clinical lab footprint with specialty genomics overlap relevant to HIC's cross-border expansion plans.
• Myriad Genetics: Established US diagnostics company offering hereditary cancer (BRACAnalysis), pharmacogenomic, and prenatal screening tests with broader portfolio reach. Overlaps HIC's oncology, pharmacogenetics (PharmaKitDx), and reproductive/prenatal (Genatal) segments as a wider-portfolio incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/healthincode
• Xx.com/_healthincode
• LinkedInlinkedin.com/company/about

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HEALTH IN CODE